Vanda Pharmaceuticals Inc. - Common Stock (VNDA) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
VNDA on Nasdaq
Shares outstanding
59,119,327
Price per share
$7.78
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
41,832,648
Total reported value
$368,861,457
% of total 13F portfolios
0%
Share change
-2,992,841
Value change
-$9,180,755
Number of holders
148
Price from insider filings
$7.78
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vanda Pharmaceuticals Inc. - Common Stock (VNDA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.1% -47% $20,206,904 -$18,941,173 4,699,280 -48% BlackRock, Inc. 31 Jan 2025
BlackRock Portfolio Management LLC 5.5% -28% $28,678,786 -$10,826,753 3,251,563 -27% BlackRock Portfolio Management LLC 31 Dec 2025
MILLENNIUM MANAGEMENT LLC 2.8% -50% $14,808,391 -$12,712,063 1,679,013 -46% Millennium Management LLC 31 Dec 2025

As of 31 Dec 2025, 148 institutional investors reported holding 41,832,648 shares of Vanda Pharmaceuticals Inc. - Common Stock (VNDA). This represents 71% of the company’s total 59,119,327 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Vanda Pharmaceuticals Inc. - Common Stock (VNDA) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 7,773,535 -13% 0% $68,562,579
VANGUARD GROUP INC 6.3% 3,731,851 +4% 0% $32,914,925
RENAISSANCE TECHNOLOGIES LLC 5.7% 3,380,961 -2.8% 0.05% $29,820,076
ACADIAN ASSET MANAGEMENT LLC 4.1% 2,410,414 +8.2% 0.03% $21,253,000
DIMENSIONAL FUND ADVISORS LP 3.6% 2,118,428 -17% 0% $18,682,439
AIGH Capital Management LLC 3.4% 1,998,431 5.2% $17,626,162
MILLENNIUM MANAGEMENT LLC 2.8% 1,679,013 -48% 0.01% $14,808,895
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,391,790 -0.02% 0% $12,278,432
STATE STREET CORP 2.1% 1,263,539 -0.59% 0% $11,144,414
Krensavage Asset Management, LLC 2% 1,180,388 0% 3.7% $10,411,000
Empire Financial Management Company, LLC 1.9% 1,108,245 +46% 2.1% $9,774,720
TWO SIGMA ADVISERS, LP 1.8% 1,049,300 +15% 0.02% $9,254,826
TWO SIGMA INVESTMENTS, LP 1.7% 978,990 +48% 0.01% $8,634,692
Connor, Clark & Lunn Investment Management Ltd. 1.3% 743,546 -18% 0.02% $6,558,076
JACOBS LEVY EQUITY MANAGEMENT, INC 1.2% 708,428 +552% 0.02% $6,248,335
AQR CAPITAL MANAGEMENT LLC 1.1% 627,006 -6.2% 0% $5,530,194
MORGAN STANLEY 1% 593,023 -7% 0% $5,230,464
FEDERATED HERMES, INC. 0.94% 554,427 -19% 0.01% $4,890,047
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.85% 500,515 +2.4% 0% $4,414,542
Jump Financial, LLC 0.8% 473,800 +243% 0.05% $4,178,916
NORTHERN TRUST CORP 0.73% 429,113 -5.6% 0% $3,784,777
GOLDMAN SACHS GROUP INC 0.69% 408,342 +20% 0% $3,601,577
JPMORGAN CHASE & CO 0.67% 396,017 +98% 0% $3,492,870
Nuveen, LLC 0.49% 291,473 +70% 0% $2,570,792
Quantinno Capital Management LP 0.44% 261,802 +218% 0% $2,309,094

Institutional Holders of Vanda Pharmaceuticals Inc. - Common Stock (VNDA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 41,832,648 $368,861,457 -$9,180,755 $8.82 148
2025 Q3 44,907,666 $224,087,329 -$589,312 $4.99 147
2025 Q2 45,005,222 $212,432,729 +$5,358,364 $4.72 137
2025 Q1 43,925,314 $201,682,351 +$2,283,938 $4.59 145
2024 Q4 43,147,771 $206,663,421 -$5,834,005 $4.79 146
2024 Q3 43,981,766 $206,261,308 +$385,141 $4.69 151
2024 Q2 43,532,710 $245,988,772 -$20,221,284 $5.65 147
2024 Q1 48,062,202 $197,420,430 -$11,386,730 $4.11 140
2023 Q4 50,696,953 $213,770,549 -$8,165,025 $4.22 154
2023 Q3 52,588,884 $227,183,918 -$23,037,768 $4.32 179
2023 Q2 56,248,075 $370,694,666 -$14,253,028 $6.59 187
2023 Q1 58,308,583 $395,914,559 +$17,232,279 $6.79 176
2022 Q4 55,589,814 $410,808,616 +$2,189,163 $7.39 186
2022 Q3 55,141,714 $544,810,424 -$11,288,828 $9.88 171
2022 Q2 56,006,392 $610,516,173 -$187,164 $10.90 166
2022 Q1 56,272,506 $636,565,420 +$17,401,270 $11.31 181
2021 Q4 54,252,447 $851,181,026 -$29,760,480 $15.69 192
2021 Q3 55,224,691 $946,649,896 +$4,381,069 $17.14 173
2021 Q2 54,791,110 $1,178,013,080 +$10,402,309 $21.51 176
2021 Q1 54,541,422 $819,510,471 -$4,488,836 $15.02 182
2020 Q4 55,039,795 $723,395,120 +$5,524,875 $13.14 170
2020 Q3 54,414,204 $525,712,121 -$8,605,614 $9.66 159
2020 Q2 55,140,491 $630,777,920 +$15,624,266 $11.44 159
2020 Q1 53,776,502 $557,290,753 +$129,584 $10.36 154
2019 Q4 52,825,174 $866,806,457 -$1,382,881 $16.41 170
2019 Q3 52,964,599 $703,437,080 -$21,562,526 $13.28 161
2019 Q2 54,287,178 $764,978,865 +$13,754,283 $14.09 158
2019 Q1 54,377,164 $1,000,565,489 +$5,340,845 $18.40 175
2018 Q4 53,011,338 $1,384,693,451 +$27,801,917 $26.13 180
2018 Q3 52,207,975 $1,198,127,037 +$80,020,008 $22.95 157
2018 Q2 49,022,523 $933,879,055 +$18,597,031 $19.05 134
2018 Q1 48,202,587 $812,206,007 +$128,627,396 $16.85 130
2017 Q4 40,872,797 $621,278,889 +$12,023,355 $15.20 125
2017 Q3 39,724,724 $711,076,419 +$17,158,833 $17.90 137
2017 Q2 38,857,064 $633,364,808 -$6,543,528 $16.30 131
2017 Q1 39,704,878 $555,846,956 +$44,096,425 $14.00 134
2016 Q4 40,641,934 $648,300,745 -$10,229,525 $15.95 141
2016 Q3 40,758,505 $678,216,752 +$66,622,806 $16.64 137
2016 Q2 37,247,837 $416,814,941 -$42,220,720 $11.19 115
2016 Q1 41,259,486 $344,882,956 -$12,846,699 $8.36 115
2015 Q4 42,551,919 $396,337,229 -$31,495,959 $9.31 116
2015 Q3 42,714,610 $481,809,118 +$465,619 $11.28 121
2015 Q2 42,413,548 $538,068,965 -$35,411,925 $12.69 109
2015 Q1 46,293,079 $430,514,637 -$27,508,593 $9.30 108
2014 Q4 47,666,210 $682,064,306 +$77,111,645 $14.32 108
2014 Q3 41,299,517 $428,691,693 +$24,205,345 $10.38 101
2014 Q2 38,482,247 $622,313,434 +$52,888,872 $16.18 110
2014 Q1 35,159,995 $571,479,438 +$57,348,441 $16.25 109